Tango Therapeutics

Yahoo Finance • 4 days ago

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Crystal Adam, President of R&D at Tango Therapeutics(NASDAQ:TNGX), reported the exercise of 27,000 stock options -- with the underlying common shares immediately sold for approximately $572,000 -- according to an SEC Form 4 filing on April... Full story

Yahoo Finance • 13 days ago

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Key Points Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position... Full story

Yahoo Finance • 24 days ago

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financi... Full story

Yahoo Finance • last month

Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following t... Full story

Yahoo Finance • last month

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock opti... Full story

Yahoo Finance • last month

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story

Yahoo Finance • last month

Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca. Continue Reading... Full story

Yahoo Finance • last month

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story

Yahoo Finance • 4 months ago

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics Sub, Inc BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver... Full story

Yahoo Finance • 5 months ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat... Full story

Yahoo Finance • 5 months ago

Tango Therapeutics launches $100M at-the-market stock offering

* Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) entered [https://seekingalpha.com/filing/52044862] a sales agreement with Leerink Partners to sell up to $100M of common stock through an at-the-market offering. * Leer... Full story

Yahoo Finance • 6 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the... Full story

Yahoo Finance • 8 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at t... Full story

Yahoo Finance • 8 months ago

Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress

TANGO THERAPEUTICS INC (NASDAQ:TNGX [https://www.chartmill.com/stock/quote/TNGX/profile]) reported its second-quarter 2025 financial results, missing revenue estimates while aligning closely with earnings per share (EPS) expectations. The... Full story

Yahoo Finance • 9 months ago

Tango Therapeutics' SWOT analysis: biotech stock's potential in precision cancer therapies

Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotechnology company focused on discovering and delivering precision cancer therapies, has been garnering attention from investors and analysts alike. The company’s innovative approach to targetin... Full story

Yahoo Finance • 10 months ago

Tango Therapeutics doses first patient in cancer drug combo trial

BOSTON - Tango Therapeutics (NASDAQ:TNGX), whose stock has surged nearly 58% over the past six months according to InvestingPro data, has dosed the first patient in a Phase 1/2 trial testing its TNG462 drug in combination with Revolution M... Full story

Yahoo Finance • 10 months ago

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient... Full story

Yahoo Finance • 10 months ago

Tango Therapeutics' SWOT analysis: stock poised for growth amid clinical trials

Tango Therapeutics (NASDAQ:TNGX), a biotechnology company specializing in innovative cancer treatments with a current market capitalization of $508 million, is attracting significant attention from investors and analysts as it approaches c... Full story

Yahoo Finance • 11 months ago

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at th... Full story

Yahoo Finance • 11 months ago

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient h... Full story